Here's a summary of Rubicon Research Limited's investor presentation: **1. Business Performance:** Rubicon Research saw impressive revenue growth of 51.6% year-over-year in Q1 FY27, reaching ₹5,343 million.

This was driven by strong performance across segments.

The company's USD revenue also increased by 32% YoY to $55 million. **2. Growth Drivers or Strategy:** The company continues to focus on its specialty product portfolio, which contributed 36% to gross profit in Q1 FY27. They are strategically managing their manufacturing mix and giving up lower-margin business to improve reliance on own manufacturing capabilities for future growth. **3. Recent Developments:** Rubicon acquired a USFDA-approved manufacturing facility in New Jersey for $2.9 million, marking their first US manufacturing footprint.

They also received two product approvals in Q1 FY27, maintaining a strong commercialization rate of 88%. **4. Key Financial Metrics:** Revenue from operations stood at ₹5,343 million in Q1 FY27, a 51.6% increase YoY.

EBITDA was ₹1,312 million, up 64.6% YoY, and PAT was ₹848 million, a 95.8% increase YoY. **5. Management Commentary / Outlook:** The company expects strong revenue visibility in the coming quarters.

They are raising their FY27 operating EBITDA margin guidance to at least 23%, up from the previous 22-23% range, despite planned investments in new initiatives.

The Pithampur plant is on track for ramp-up from Q1CY27.